Drug-eluting Stents: Potential Applications for Peripheral Arterial Occlusive Disease

Hoffmann, 2000, Coronary instent restenosis—predictors, treatment and prevention, Eur Heart J, 21, 1739, 10.1053/euhj.2000.2153 Savage, 1998, Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries. Stent Restenosis Study (STRESS) Investigators, J Am Coll Cardiol, 31, 307, 10.1016/S0735-1097(97)00511-1 Vom Dahl, 2002, Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST), Circulation, 105, 583, 10.1161/hc0502.103347 Lansky, 1999, Comparative analysis of early and late angiographic outcomes using two quantitative algorithms in the balloon versus optimal atherectomy trial (BOAT), Am J Cardiol, 83, 1611, 10.1016/S0002-9149(99)00166-6 Tripuraneni, 2002, Coronary artery radiation therapy for the prevention of restenosis after percutaneous coronary angioplasty, II: outcomes of clinical trials, Semin Radiat Oncol, 12, 17, 10.1053/srao.2002.28659 Tsuchikane, 1999, Final results of the stent versus directional coronary atherectomy randomized trial (START), J Am Coll Cardiol, 34, 1050, 10.1016/S0735-1097(99)00324-1 Cohen, 2002, Cost effectiveness of gamma radiation for treatment of in-stent restenosis: results from the GAMMA 1 trial, Circulation, 106, 691, 10.1161/01.CIR.0000023625.12626.29 Ahmadi, 2001, Carotid artery stenting: effect of learning curve and intermediate-term morphological outcome, J Endovasc Ther, 8, 539, 10.1583/1545-1550(2001)008<0539:CASEOL>2.0.CO;2 Yoon, 2001, A newly designed nitinol stent: early clinical experience in the treatment of iliac artery stenoses and occlusions, Korean J Radiol, 2, 145, 10.3348/kjr.2001.2.3.145 Rundback, 1998, Renal artery stent placement for the management of ischemic nephropathy, J Vasc Interv Radiol, 9, 413, 10.1016/S1051-0443(98)70292-1 Strecker, 2001, Popliteal artery stenting using flexible tantalum stents, Cardiovasc Intervent Radiol, 24, 168, 10.1007/s002700002526 Gray, 1997, Limitations of percutaneous transluminal angioplasty with stenting for femoropopliteal arterial occlusive disease, Semin Vasc Surg, 10, 8 Cheng, 2001, Endovascular stenting of superficial femoral artery stenosis and occlusions: results and risk factor analysis, Cardiovasc Surg, 9, 133, 10.1016/S0967-2109(00)00109-5 Fischman, 1994, A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators, N Engl J Med, 331, 496, 10.1056/NEJM199408253310802 Grimm, 2001, Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions, J Vasc Interv Radiol, 12, 935, 10.1016/S1051-0443(07)61572-3 Kasaoka, 1998, Angiographic and intravascular ultrasound predictors of in-stent restenosis, J Am Coll Cardiol, 32, 1630, 10.1016/S0735-1097(98)00404-5 Suselbeck, 2001, Role of vessel size as a predictor for the occurrence of in-stent restenosis in patients with diabetes mellitus, Am J Cardiol, 88, 243, 10.1016/S0002-9149(01)01633-2 Deutschmann, 2001, Placement of Hemobahn stent-grafts in femoropopliteal arteries: early experience and midterm results in 18 patients, J Vasc Interv Radiol, 12, 943, 10.1016/S1051-0443(07)61574-7 Strecker, 1997, Femoropopliteal artery stent placement: evaluation of long term success, Radiology, 205, 375, 10.1148/radiology.205.2.9356617 Leon, 2001, Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting, N Engl J Med, 344, 250, 10.1056/NEJM200101253440402 Waksman, 2000, Intracoronary beta-radiation therapy inhibits recurrence of in-stent restenosis, Circulation, 102, 951 Kuntz, 2001, Intravascular sonotherapy in human coronary arteries: first results of a feasibility trial (abstr), J Am Coll Cardiol, 37, 45A Rockson, 2000, Photoangioplasty: an emerging clinical cardiovascular role for photodynamic therapy, Circulation, 102, 591, 10.1161/01.CIR.102.5.591 Tsuchikane, 1999, Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty, Circulation, 99, 21, 10.1161/01.CIR.100.1.21 Duda, 2002, Next generation balloon expandable stents, Intervention, 5, 80 Ahn, 1999, Preventive effects of the heparin-eluting stent on restenosis in the porcine model, Cathet Cardiovasc Intervent, 48, 324, 10.1002/(SICI)1522-726X(199911)48:3<324::AID-CCD20>3.0.CO;2-K Herrmann, 1999, Antithrombogenic coating of stents using a biodegradable drug delivery technology, Thromb Haemost, 82, 51, 10.1055/s-0037-1614629 Alt, 2000, Inhibition of neointima formation after experimental coronary artery stenting—a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost, Circulation, 101, 1453, 10.1161/01.CIR.101.12.1453 Whelan, 2000, Biocompatibility of phosphorylcholine eluting stents in normal porcine coronary arteries, Heart, 83, 338, 10.1136/heart.83.3.338 Karrillon, 1996, Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30day clinical outcome of the French Multicenter Registry, Circulation, 94, 1519, 10.1161/01.CIR.94.7.1519 Taniuchi, 2001, Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population, Circulation, 104, 539, 10.1161/hc3001.093435 Van der Giessen, 2001, Edge effect of 32p radioactive stents is caused by the combination of chronic stent injury and radioactive dose falloff, Circulation, 104, 2236, 10.1161/hc4301.097873 Ye, 1998, Bioresorbable microporous stents deliver recombinant adenovirus gene transfer vectors to the arterial wall, Ann Biomed Eng, 26, 398, 10.1114/1.62 Tamai, 2000, Initial and 6-months results of biodegradable poly-l-lactide acid coronary stents in humans, Circulation, 102, 399, 10.1161/01.CIR.102.4.399 Tsuji, 2001, One year follow-up of biodegradable selfexpanding stent implantation in humans (abstr), J Am Coll Cardiol, 37, 1A Regar, 2001, Stent development and local drug delivery, Br Med Bull, 59, 227, 10.1093/bmb/59.1.227 Teirstein, 2001, Living the dream of no restenosis, Circulation, 104, 1996, 10.1161/circ.104.17.1996 Marx, 2001, The development of rapamycin and its application to stent restenosis, Circulation, 104, 852, 10.1161/01.CIR.104.8.852 Zohlnhofer, 2001, Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: detection of FK506-binding protein upregulation, Circulation, 103, 1396, 10.1161/01.CIR.103.10.1396 Roque, 2000, Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model, Atherosclerosis, 153, 315, 10.1016/S0021-9150(00)00421-4 Gallo, 1999, Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle, Circulation, 99, 2164, 10.1161/01.CIR.99.16.2164 Groth, 1999, Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal transplant Study Group, Transplantation, 67, 1036, 10.1097/00007890-199904150-00017 Suzuki, 2001, Stent based delivery of sirolimus reduces neointimal formation in a porcine coronary model, Circulation, 104, 1188, 10.1161/hc3601.093987 Sousa, 2001, Lack of neointimal proliferation after implantation of sirolimus-eluting stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study, Circulation, 103, 192, 10.1161/01.CIR.103.2.192 Leon Sousa, 2001, Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular follow-up, Circulation, 104, 2007, 10.1161/hc4201.098056 Beyar, 2001, The sirolimus eluting stent: will the Achilles Heel of interventional cardiology finally be cured?, Eur Heart J, 22, 2054, 10.1053/euhj.2001.2950 Serruys, 2002, Rapamycin eluting stent: the onset of a new era in interventional cardiology, Heart, 87, 305, 10.1136/heart.87.4.305 Sousa Morice, 2001, The RAVEL study: a randomized study with the Sirolimus-eluting balloon-expandable BX™ Velocity stent in the treatment of patients with de novo native coronary artery lesions (abstr), Eur Heart J, 22, 484 Morice, 2002, A randomized comparison of a Sirolimus-eluting stent with a standard stent for coronary revascularization, N Engl J Med, 346, 1773, 10.1056/NEJMoa012843 Rensing, 2001, Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasound follow-up, Eur Heart J, 22, 2125, 10.1053/euhj.2001.2892 Leon Grube Duda, 2002, Sirolimus eluting stents for the treatment of obstructive superficial femoral artery disease: 6-months results, Circulation, 106, 1505, 10.1161/01.CIR.0000029746.10018.36 Gray, 1997, High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long segment superficial femoral artery disease after suboptimal angioplasty, J Vasc Surg, 25, 74, 10.1016/S0741-5214(97)70323-9 Jahnke, 2002, Endovascular placement of self-expanding nitinol coil stents for the treatment of femoropopliteal obstructive disease, J Vasc Interv Radiol, 13, 257, 10.1016/S1051-0443(07)61718-7 Cejna, 2001, PTA versus Palmaz stent placement in femoropopliteal artery obstructions; a multicenter prospective randomized study, J Vasc Interv Radiol, 12, 23, 10.1016/S1051-0443(07)61397-9 Do, 1992, A comparison study of self expandable stents versus balloon angioplasty alone in femoropopliteal artery occlusions, Cardiovasc Interv Radiol, 15, 306, 10.1007/BF02733955 Farb, 2001, Pathological analysis of local delivery of paclitaxel via a polymer-eluting stent, Circulation, 104, 473, 10.1161/hc3001.092037 Heldman, 2001, Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis, Circulation, 103, 2289, 10.1161/01.CIR.103.18.2289 Hong, 2001, Paclitaxel-eluting GianturcoRoubin II (GR II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model, Coron Artery Dis, 12, 513, 10.1097/00019501-200109000-00011 Axel, 1997, Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery, Circulation, 96, 636, 10.1161/01.CIR.96.2.636 Baumbach, 1999, Local drug delivery: impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall, Cathet Cardiovasc Intervent, 47, 102, 10.1002/(SICI)1522-726X(199905)47:1<102::AID-CCD22>3.0.CO;2-G Hwang, 2001, Physiological transport forces govern drug distribution for stent-based delivery, Circulation, 104, 600, 10.1161/hc3101.092214 Stone Stone Chevalier Honda, 2001, Novel drug delivery stent—intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system, Circulation, 104, 380, 10.1161/hc2901.094149 De la Fuente, 2001, Initial results of the Quanam drug eluting stent (QuaDS-QP-2) registry (BARDDS) in human subjects, Cathet Cardiovasc Intervent, 53, 480, 10.1002/ccd.1207 Liistro, 2001, Late acute thrombosis after paclitaxel eluting stent implantation, Heart, 86, 262, 10.1136/heart.86.3.262 Liistro, 2002, First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome, Circulation, 105, 1883, 10.1161/01.CIR.0000016042.69606.61 Zilberman, 2001, Structured drug-loaded bioresorbable films for support structures, J Biomater Sci, 12, 875, 10.1163/156856201753113079 Muller, 1994, Site specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation, Coron Artery Dis, 5, 435, 10.1097/00019501-199405000-00010 Lincoff, 1997, Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model, J Am Coll Cardiol, 29, 808, 10.1016/S0735-1097(96)00584-0 Strecker, 1998, Effect on intimal hyperplasia of dexamethasone released from eluting metal stents compared with non-eluting stents in canine femoral arteries, Cardiovasc Intervent Radiol, 21, 487, 10.1007/s002709900309 De Scheerder Lovdahl, 2000, The synthetic metalloproteinase inhibitor batimastat suppresses injury-induced phosphorylation of MAP kinase ERK1/ERK2 and phenotypic modification of arterial smooth muscle cells in vitro, J Vasc Res, 37, 345, 10.1159/000025750 de Smet, 2000, Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig, Circulation, 101, 2962, 10.1161/01.CIR.101.25.2962 Zhu, 2000, Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis, Lab Invest, 80, 545, 10.1038/labinvest.3780060 De Scheerder Linnemaier Chandrasekar, 2000, Local delivery of 17-beta-estradiol decreases neointimal hyperplasia after coronary angioplasty in a porcine model, J Am Coll Cardiol, 36, 1972, 10.1016/S0735-1097(00)00940-2 Do, 1996, 17 beta-estradiol inhibits proliferation and migration of human vascular smooth muscle cells: similar effects in cells from postmenopausal females and in males, Cardiovasc Res, 32, 980 New Stone Diestel